After 23andMe’s Board Revolt, Wojcicki’s Nonprofit Bought Its Assets

Seven independent directors resigned from 23andMe on September 17, 2024, leaving co-founder and then-CEO Anne Wojcicki as the board’s only remaining member. That rupture is no longer the company’s latest development: 23andMe Holding Co. subsequently entered Chapter 11, and its core consumer-genetics and research assets were sold.

The sale closed on July 14, 2025, with a nonprofit led by Wojcicki acquiring substantially all of those assets for $305 million. The former public company began winding down, while the testing and research businesses continued under 23andMe Research Institute. A 2026 settlement over the earlier data breach shows that responsibility for customers’ genetic information remains a live issue after the ownership change.

What the directors actually said when they resigned

The directors’ departure was extraordinary in scale, but “in disgust” is not a documented description of their position. The company’s September 2024 Form 8-K identifies the seven departing non-employee directors as Roelof Botha, Patrick Chung, Sandra Hernández, Neal Mohan, Valerie Montgomery Rice, Richard Scheller and Peter Taylor. Their resignations took effect immediately.

The filing attributes their decision to a disagreement with Wojcicki about 23andMe’s strategic direction and to her concentrated voting power. It does not allege personal misconduct or characterize the directors’ emotional state. The defensible account is therefore a governance breakdown: every non-employee director left because the board and the controlling founder could not agree on the company’s path.

The resignations also emptied the board committees responsible for core public-company functions. Departing directors had occupied the audit and compensation committees, while Hernández and Taylor served on the special committee evaluating strategic alternatives. Rebuilding the board was consequently an operational necessity, not merely a matter of replacing prominent names.

The dispute was about a company already under severe pressure

Wojcicki had sought to take 23andMe private after its market value fell sharply from the valuation attached to its 2021 public listing. The independent directors wanted an actionable transaction that could be evaluated on behalf of unaffiliated shareholders; Wojcicki’s voting position meant that any strategic process also had to contend with her ability to influence the outcome.

The mass resignation did not itself put 23andMe into bankruptcy, and the available filings do not establish that it caused the later collapse. It did, however, expose how little agreement remained at the top of a business facing persistent operating losses, a weakened share price and the consequences of a major security incident. In November 2024, the reconstituted board approved workforce reductions and the closure of substantially all operations in the therapeutics segment.

By March 23, 2025, 23andMe Holding Co. and several subsidiaries had filed voluntary Chapter 11 petitions in the Eastern District of Missouri. Wojcicki stepped down as chief executive when the bankruptcy process began but remained involved as a director and bidder for the assets.

Bankruptcy produced the outcome the board dispute did not

The bankruptcy auction initially appeared likely to transfer the business to Regeneron Pharmaceuticals. A later round of bidding instead selected TTAM Research Institute, a California nonprofit public benefit corporation founded and led by Wojcicki.

An SEC filing recording the completed transaction says the buyer, subsequently named 23andMe Research Institute, acquired substantially all of the debtors’ assets for a total price of $305 million on July 14, 2025. Those assets included the Personal Genome Service and research-services operations. The filing describes the institute as a Wojcicki affiliate and therefore treats the deal as a related-party transaction.

This distinction resolves an apparent contradiction in the company’s status. The debtor, 23andMe Holding Co., said it was winding down and expected to cease to exist after distributing its remaining assets. The consumer genetics service did not disappear with it: the service and research assets moved to the nonprofit institute. Saying simply that “23andMe survived” or “23andMe shut down” misses the separation between the former listed corporation and the operations purchased from it.

The sale turned a shareholder conflict into a data-governance question

The asset transfer mattered differently to investors and customers. For investors, the decisive development was the bankruptcy sale and wind-down of the public holding company. For customers, the central question was who would control genetic information, biological samples and research permissions after the transaction.

State officials challenged aspects of the sale and pressed for safeguards governing the new custodian. A July 2026 multistate settlement announcement says the assets, including consumer data, went to the nonprofit now registered as 23andMe Research Institute. It also records commitments involving stronger security requirements, risk analysis, a privacy advisory board, compliance with comprehensive privacy laws and continued consumer deletion rights.

The same announcement addressed claims arising from the 2023 breach that affected 6.9 million people worldwide. States received $150 million in allowed bankruptcy claims, although the expected recovery from the finite estate was limited to $18 million. A separate $46.75 million class-action settlement covered eligible affected US consumers who had submitted claims by the stated deadline.

These settlements do not erase the breach or guarantee that another incident cannot occur. They establish enforceable consequences and additional governance measures after the asset transfer. Customers retain the practical ability to request deletion, but previously shared or used research information may be subject to the terms that applied when consent was granted; account holders should examine their own consent and sample-storage settings rather than assume every category of information is handled identically.

Why the 2024 revolt still matters

The resignations did not remove Wojcicki from 23andMe’s future. Less than a year later, an organization she founded and led owned the company’s principal testing and research assets. The route was not the private-company transaction debated in 2024, but a court-supervised bankruptcy sale after the original corporation’s financial position deteriorated further.

That outcome gives the board dispute its lasting significance. The directors’ warning was about governance under concentrated control; the later transaction returned the operating assets to a Wojcicki-led entity while ending the old public-company structure. At the same time, pressure from courts and state officials added privacy obligations that constrain how the successor organization handles unusually sensitive customer information.

Also read:

• Why OpenAI’s Sora Crashed and Burned After Just 1.5 Years: The Video Slop That Ate Itself
• How’s Allbirds Doing After Its Wild AI Pivot? Now It’s Smartbird — and the Sneakers Are Officially History
• After Years of Chasing Money, OpenAI Reportedly Giving Up on Being a “Nonprofit”